Scientific Presentations & Publications

Drug development backed by sound research.

The publications and presentations highlighted below represent a sample of the team’s innovative research published by the Coherus team and our collaborators.

04/08/24

Characterization of CHS-1000, an Fc-modified anti-ILT4 monoclonal antibody for reprogramming suppressive myeloid cells in solid tumors

Rajasekaran, N., et al. 2024 AACR Annual Meeting

02/29/24

Toripalimab, a Next-Generation Designed Anti-PD-1 Antibody for Treatment of Nasopharyngeal Carcinoma

Rajasekaran, et al. 2024 Multidisciplinary Head and Neck Cancer Symposium

02/29/24

CHS-114: a Cytolytic Anti-CCR8 Antibody that Depletes Tumor-Infiltrating Regulatory T Cells as a Treatment for Head and Neck Squamous Cell Carcinoma

Rajasekaran, et al. 2024 Multidisciplinary Head and Neck Cancer Symposium

02/24/24

Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells

Rajasekaran, N., Wang, X., Ravindranathan, S. et al. Cancer Immunol Immunother 73, 60 (2024)

01/19/24

Results from a phase 2 study of triplet blockade of the IL-27, PD-(L)1, and VegF pathways with casdozokitug (casdozo, CHS-388) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC)

Li, Daneng, et al. 2024 ASCO GI Cancers Symposium

11/28/23

Toripalimab plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma

Mai, Hai-Qiang, et al. Journal of the American Medical Association (JAMA). 2023;330(20):1961-1970. doi:10.1001/jama.2023.20181

11/06/23

Casdozokitug (casdozo, CHS-388), a first-in-class IL-27 targeting antibody as monotherapy or in combination with pembrolizumab (pembro) in treatment-refractory non-small cell lung cancer (NSCLC)

Thomas Marron, et al. 2023 ESMO Immuno-Oncology Congress

11/04/23

Characteristics of toripalimab: a next generation anti-PD-1 antibody with potent T cell activation and enhanced clinical efficacy irrespective of PD-L-1 status

Ravindranathan S, Wang X, Chin DJ, et al. Journal for ImmunoTherapy of Cancer. 2023;11:doi: 10.1136/jitc-2023-SITC2023.0468.

10/14/23

Toripalimab, an anti-PD-1 antibody that demonstrates potent T cell activation and enhanced clinical efficacy irrespective of PD-L1 status

Xiaoguang Wang, et al. AACR-NICI-EORTIC International Conference on Molecular Targets and Cancer Therapeutics

06/06/23

Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations

Jie Wang, et al. ASCO Annual Meeting 2023

1234

We have multiple novel immuno-oncology programs currently in our development pipeline.

See our Pipeline